| Document |
Document Title |
|
WO/2022/244551A1 |
The purpose of the present invention is to provide a treatment material used for the treatment of a disease a symptom of which is mitigated or treated through reduction of the phosphorus concentration in blood. The treatment material acc...
|
|
WO/2022/241549A1 |
GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fra...
|
|
WO/2022/245933A1 |
The present invention features new testosterone undecanoate (TU) dosing regimens, e.g., for testosterone replacement therapy. The TU may be formulated with phytosterols or phytosterol esters.
|
|
WO/2022/241404A1 |
The present disclosure relates to polycyclic (e.g., fused tetracyclic) liver X receptor (LXR) modulators, synthetic methods for preparing such LXR modulators, and methods of using such LXR modulators to treat a disease or condition that ...
|
|
WO/2022/237780A1 |
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compo...
|
|
WO/2022/237781A1 |
Provided are an amide derivative and an application thereof in medicine, in particular, an amide derivative as represented by formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated pro...
|
|
WO/2022/241257A1 |
Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinu...
|
|
WO/2022/241167A1 |
The present disclosure provides delivery constructs comprising a carrier derived from a mono-ADP-ribosyl transferase (mART). The mART can be from an Aeromonas, Chromobacterium, Collimonas, Shewanella, Janthinobacterium, Serratia, or Acin...
|
|
WO/2022/240476A1 |
Described herein are novel bithiazol compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 nM, induce sensitization of the cells to doxorubicin strong activity in a recombinant LOX...
|
|
WO/2022/233768A1 |
A precursor designated as DAZTA5-PPA2 for PET/CT diagnosis and nuclear therapy|of SSR active lesions with radioisotopes 68Ga and 177Lu provides improved|affinity, specificity and imaging of small metastases.
|
|
WO/2022/224164A1 |
Provided herein are novel compounds comprising a GLP-1 compound and a fatty acid or fatty acid derivative, the manufacture of said novel compounds and the use thereof.
|
|
WO/2022/222886A1 |
The present invention relates to an elagolix sodium composition. Specifically, disclosed is an elagolix sodium composition, which comprises: elagolix sodium as shown in formula (I), and a pharmaceutically acceptable alkalizing agent, fil...
|
|
WO/2022/221886A1 |
Provided herein are pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further p...
|
|
WO/2022/221661A1 |
The present disclosure generally relates to pharmaceutical compositions comprising N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propa
n-2-yl)phenoxy) methyl)pyrimidin-2-yl)methanesulfonamideN-(4-((4-(2-(3-chlor
o-4-(2-chloroeth...
|
|
WO/2022/215048A1 |
The present invention refers to a process for the industrial-scale preparation of 17β-hydroxy- 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carb
oxylic acid y-lactone, known by the common name of Drospirenone, in the form of ...
|
|
WO/2022/204771A1 |
The present application is a biodegradable implant of isolated triiodothyronine (T3), isolated triiodothyronine sulfate (T3S), isolated thyroxine (T4), a combination of triiodothyronine (T3) and thyroxine (T4), or a combination of triiod...
|
|
WO/2022/206587A1 |
A polypeptide compound having a structure shown in formula I, or a stereoisomer, mixture or pharmaceutically acceptable salt thereof. Experimental results show that the polypeptide compound can effectively exhibit high agonistic activity...
|
|
WO/2022/211810A1 |
Methods and formulations of treatment for menstrual complications, gestational complications, and to prolong gestation are described. Treatments include administration of a compound related to regulation of gestational progress or uterin...
|
|
WO/2022/204481A1 |
Provided herein are pyrazolopyrimidinone compounds and pharmaceutical compositions comprising said compounds.
|
|
WO/2022/199577A1 |
The present invention belongs to the technical field of pharmaceutical crystal chemistry, and relates in particular to anhydrous polymorphs of an androgen receptor antagonist, a preparation method therefor, and a use thereof. In particul...
|
|
WO/2022/204474A1 |
The present disclosure provides engineered cells (e.g., T cells) comprising a chimeric antigen receptor (CAR) and a therapeutic peptide, and methods of use thereof.
|
|
WO/2022/194073A1 |
Disclosed in the present invention are a salt form and a crystal form of a 1,2,4-triazine-3,5-dione (Formula I) compound, a preparation method therefor, and the use thereof in the treatment and/or the preparation of a drug. The use is to...
|
|
WO/2022/194278A1 |
A series of phenol compounds and the use thereof. Specifically disclosed are a compound as represented by formula (III) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/194287A1 |
Disclosed are a bicyclic pyridinone compound and the use thereof, and particularly disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/192428A1 |
The present disclosure provides GLP-1R agonists of Formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/189530A1 |
The present invention relates to sepsis, and to compounds useful in the prevention and treatment of subjects suffering from sepsis or at risk for developing sepsis. The invention particularly relates to compounds that inhibit the AR cell...
|
|
WO/2022/192533A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor¬ interacting protein-1 (RIP1) kinase inhibitor compounds of formula (I), as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. ...
|
|
WO/2022/192430A1 |
The present disclosure provides GLP-1R agonists of formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/186355A1 |
A problem addressed by the present disclosure, at least, is to provide a composition for the production of 6,3'-dihydroxyequol. The problem is solved by a composition that includes an equol-containing composition, a first enzyme or a fir...
|
|
WO/2022/184177A1 |
Disclosed in the present invention is an aromatic compound, a preparation method therefor, and an application thereof. The present invention provides a compound as represented by formula I or a pharmaceutically acceptable salt thereof. T...
|
|
WO/2022/184849A1 |
Compounds of formula (I)
|
|
WO/2022/184176A1 |
Disclosed are a pharmaceutical composition containing ethanol and a use thereof. The pharmaceutical composition can be used in vivo for animals, and is prepared from the following raw material: ethanol having a concentration no lower tha...
|
|
WO/2022/182954A1 |
Embodiments of the instant disclosure relate to novel methods for treatment of one or more pathologic entities of Type 2 diabetes. In certain embodiments, methods concern reducing the risk of developing, preventing and/or treating a path...
|
|
WO/2022/180398A1 |
The present Invention relates to a pellet comprising melatonin and methods of treating insomnia.
|
|
WO/2022/171018A1 |
The present invention relates to a substituted benzopyrimidine or pyridopyrimidine amine inhibitor, and a preparation method therefor and the use thereof. Specifically, the compound of the present invention has a structure as shown in fo...
|
|
WO/2022/173315A1 |
The present disclosure generally relates to methods of and uses for treating Prader-Willi Syndrome (PWS) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formulas I, II, III or IV,...
|
|
WO/2022/173284A1 |
An oral delivery salt nano-precipitate for oral delivery of protein therapeutics such as insulin. The salt nano-precipitate comprises a cation-providing inorganic metal salt and an anion-providing salt. The protein molecule is bound to t...
|
|
WO/2022/171101A1 |
The present application relates to a steroid conjugate, and in particular, to a compound or a tautomer, a mesomer, a racemate, an enantiomer, and a diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt...
|
|
WO/2022/166810A1 |
The present disclosure relates to a fused azatricyclic derivative, a preparation method therefor, and an application thereof in medicine. In particular, the present disclosure relates to a fused azatricyclic derivative represented by gen...
|
|
WO/2022/163852A1 |
The purpose of the present invention is to provide a composition for inhibiting the expression of angiotensin converting enzyme 2 (ACE2) and/or TMPRSS2. Provided is a composition for inhibiting the expression of angiotensin converting en...
|
|
WO/2022/161166A1 |
A targeting chimeric compound, a pharmaceutical composition comprising same, a preparation method therefor and use thereof. The targeting chimeric compound is as represented by general formula (I), and each substituent in the general for...
|
|
WO/2022/161377A1 |
Provided are a pharmaceutical composition comprising a glucopyranosyl derivative and a preparation method thereof. The pharmaceutical composition can effectively improve the dissolution and fluidity of the drug, and has high content unif...
|
|
WO/2022/160138A1 |
The present invention relates to a benzoxazine-4-one compound represented by formula (I) that acts as a glycogen phosphorylase inhibitor, a preparation method therefor, and a use thereof in a drug for the treatment and/or prevention of d...
|
|
WO/2022/156449A1 |
The present invention relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the compound and pharmaceutically acceptab...
|
|
WO/2022/158595A1 |
The purpose of the present invention is to provide a novel agent for promoting the absorption of isoflavone into the body. The present invention provides an isoflavone absorption promoter, the isoflavone absorption promoter being an agen...
|
|
WO/2022/144021A1 |
The present invention relates to a pharmaceutical composition, comprising (a) Dorzagliatin, or an isotopic marker, enantiomer, diastereoisomer, pharmaceutically acceptable salt, hydrate, solvate, or crystalline form thereof; and (b) a GL...
|
|
WO/2022/142977A1 |
Provided is the use of an HrpZ-type multi-mimotope ligand protein in foods, cosmetics, health care products or pharmaceuticals. The HrpZ-type multi-mimotope ligand protein comprises HrpZPsa, HrpZPsm, HrpZPss, HrpZPst, HrpZPsap, HrpZPsr, ...
|
|
WO/2022/143985A1 |
Disclosed in the present invention are a pyridine-2-amine derivative and a pharmaceutical composition and use thereof. The pyridine-2-amine derivative can be used as a TLR8 selective agonist, has the characteristics of high selectivity, ...
|
|
WO/2022/142385A1 |
The present invention provides a method for refining dienogest. The method is a recrystallization method. The present invention belongs to the technical field of medicine synthesis. The refining of dienogest comprises the following steps...
|
|
WO/2022/143574A1 |
The present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. Activity experiment results show that the 2-pyridone derivative provided i...
|
